Moderna, Inc. (NASDAQ:MRNA) Given Average Rating of “Reduce” by Analysts

Moderna, Inc. (NASDAQ:MRNA) has been assigned a consensus rating of “Reduce” from the eighteen brokerages that are covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $28.7692.

Several brokerages recently weighed in on MRNA. TD Cowen reissued a “hold” rating on shares of Moderna in a research note on Thursday, January 29th. Jefferies Financial Group reaffirmed a “hold” rating on shares of Moderna in a report on Monday, January 5th. Barclays assumed coverage on Moderna in a research note on Wednesday, January 28th. They issued an “equal weight” rating and a $25.00 price target for the company. Morgan Stanley cut their price objective on Moderna from $30.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. Finally, Royal Bank Of Canada reissued a “sector perform” rating on shares of Moderna in a research report on Monday, January 12th.

Insider Buying and Selling at Moderna

In related news, Director Noubar Afeyan sold 23,853 shares of Moderna stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $29.48, for a total transaction of $703,186.44. Following the completion of the transaction, the director owned 3,924 shares of the company’s stock, valued at $115,679.52. This trade represents a 85.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 10.90% of the stock is currently owned by company insiders.

Institutional Trading of Moderna

Large investors have recently bought and sold shares of the business. Rothschild Investment LLC grew its stake in Moderna by 94.1% in the second quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock valued at $25,000 after acquiring an additional 446 shares during the period. Atlantic Union Bankshares Corp acquired a new position in shares of Moderna during the second quarter worth approximately $26,000. MUFG Securities EMEA plc bought a new position in shares of Moderna in the 2nd quarter worth $28,000. Whittier Trust Co. acquired a new stake in Moderna in the 2nd quarter valued at $28,000. Finally, Flagship Harbor Advisors LLC bought a new stake in Moderna during the 4th quarter valued at $31,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Price Performance

MRNA opened at $41.99 on Wednesday. Moderna has a fifty-two week low of $22.28 and a fifty-two week high of $55.20. The company’s 50 day moving average price is $36.37 and its two-hundred day moving average price is $29.66. The firm has a market capitalization of $16.41 billion, a price-to-earnings ratio of -5.20 and a beta of 1.32.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Signed a five-year strategic agreement with the Mexican government to supply respiratory vaccines and transfer mRNA manufacturing technology to local partner Liomont — strengthens revenue visibility in Latin America and builds production resilience. Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico
• Positive Sentiment: High investor interest and media endorsements (e.g., Jim Cramer) are keeping momentum and retail attention on Moderna amid excitement around its pipeline (including personalized cancer vaccine programs). Jim Cramer on Moderna
• Neutral Sentiment: Moderna says the FDA’s RTF did not raise safety or efficacy concerns and the company does not expect an impact to its 2026 financial guidance; it has requested a Type A meeting and notes mRNA‑1010 is under review in the EU, Canada and Australia — these factors could limit near-term earnings risk but leave U.S. approval uncertain. Moderna Receives Refusal-to-File Letter
• Neutral Sentiment: Upcoming Q4/2025 earnings (scheduled Feb. 13) remain a near-term catalyst — analysts expect pipeline and COVID-vaccine sales updates could influence sentiment regardless of the RTF. Earnings preview
• Negative Sentiment: FDA refused to start review of the flu-vaccine application, issuing an RTF because the pivotal 40,000‑patient trial did not use the “best‑available” U.S. comparator for older adults per the agency — a rare regulatory setback that delays potential U.S. market access and revenue from an important respiratory product. WSJ: FDA refuses to review Moderna’s flu vaccine
• Negative Sentiment: Broader regulatory headwinds under the current U.S. health administration — including tighter vaccine review expectations — raise execution risk for mRNA programs in the U.S., potentially slowing approvals and commercial timelines. Reuters: FDA refuses review
• Negative Sentiment: Recent legal developments (denial of immunity in a high‑stakes vaccine patent case) add litigation risk and potential financial exposure that investors should monitor. Yahoo Finance: Patent immunity denied

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.